Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia.

Stacy E CroteauDunlei ChengAlice J CohenChris E HolmesLynn M MalecMichael SilveyCourtney Dawn ThornburgAllison P WheelerPeter A KouidesLeslie J RaffiniEllis J Neufeld

Published in: Haemophilia : the official journal of the World Federation of Hemophilia (2019)

Haemophilia treatment centre region and patient age impact the rate of adoption of EHL products; however, EHL prescribing continues to rise nationally, particularly for EHL FIX. Careful attention to annual cost of prophylaxis is imperative as the decrease in median EHL prophylaxis consumption is not offset by the higher unit cost of these products. It is unclear how further growth in use of EHLs will be impacted by emerging non-factor replacement and gene therapies.

Keyphrases

primary care
working memory
emergency department
early onset
genome wide
drug induced
replacement therapy
adverse drug